Gain-of-function SOS1 mutations cause a distinctive form of Noonan syndrome.
Authors:
Tartaglia, M Pennacchio, LA Zhao, C Yadav, KK Fodale, V Sarkozy, A Pandit, B Oishi, K Martinelli, S Schackwitz, W Ustaszewska, A Martin, J Bristow, J Carta, C Lepri, F Neri, C Vasta, I Gibson, K Curry, CJ Siguero, JP Digilio, MC Zampino, G Dallapiccola, B Bar-Sagi, D Gelb, BD
Citation:
Tartaglia M, etal., Nat Genet. 2007 Jan;39(1):75-9. Epub 2006 Dec 13.
Noonan syndrome is a developmental disorder characterized by short stature, facial dysmorphia, congenital heart defects and skeletal anomalies. Increased RAS-mitogen-activated protein kinase (MAPK) signaling due to PTPN11 and KRAS mutations causes 50% of cases of Noonan syndrome. Here, we report that 22 of 129 individuals with Noonan syndrome without PTPN11 or KRAS mutation have missense mutations in SOS1, which encodes a RAS-specific guanine nucleotide exchange factor. SOS1 mutations cluster at codons encoding residues implicated in the maintenance of SOS1 in its autoinhibited form. In addition, ectopic expression of two Noonan syndrome-associated mutants induces enhanced RAS and ERK activation. The phenotype associated with SOS1 defects lies within the Noonan syndrome spectrum but is distinctive, with a high prevalence of ectodermal abnormalities but generally normal development and linear growth. Our findings implicate gain-of-function mutations in a RAS guanine nucleotide exchange factor in disease for the first time and define a new mechanism by which upregulation of the RAS pathway can profoundly change human development.